seizure; her legs are going numb; it is affecting her arthritis; anxiety; pregnant; she had a feeling that she had not being served what she supposed to be getting with gabapentin, may not be a gabapentin it may be something else; This is a spontaneous report from a contactable other HCP (patient). A pregnant female patient received BNT162B2 (COVID-19 Vaccine - Manufacturer Unknown), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as single dose for COVID-19 immunisation. The patient also received olanzapine (ZYPREXIA) and Gabapentin. The patient medical history included autism and "dwarfinated midgetism" of Gini variety, arthritis pain. The patient's concomitant medications included cefixime (FLEXERIL) for muscle condition, aripiprazole (ABILIFY) and gabapentin (NEURONTIN). The patient stated her legs were going numb and it was affecting her arthritis. The patient stated that she had a seizure disorder and seizures not due to the medication olanzapine. The patient wanted a cease and desist order and did not want the medication but the hospital kept giving it to her. The patient stated that she was on gabapentin and aripiprazole and did not think that the medication should be mixed. The patient sated that aripiprazole was fine. The patient sated that this is for olanzapine and gabapentin. The patient stated that she did not want aripiprazole and olanzapine. The patient stated this is for other than any antipsychotics. The patient did not need to be on psychotic drugs. The patient stated that she recently got the Covid shot. The patient mentioned going to the mental health group program for her anxiety. The patient also stated that she had a feeling that she had not being served what she supposed to be getting with gabapentin, may not be a gabapentin it may be something else, was not working the same way, also it may be old especially with the COVID in the area they should not be serving drugs that are not a proper drugs, not a proper medications. The action taken of COVID-19 Vaccine was not applicable. The action taken of other suspect products was unknown. The outcome of the events was unknown.   Pfizer is a marketing authorization holder of Gabapentin in the country of incidence or the country where the product was purchased (if different). This may be a duplicate report if another marketing authorization holder of Gabapentin has submitted the same report to the regulatory authorities.  The lot number for the vaccine, (BNT162B2), was not provided and will be requested during follow up.; Sender's Comments: A contributory role of BNT162B2 to the event seizure cannot be fully excluded based on temporal relationship and lack of reported alternative explanation at this time. However, the information provided is very limited and does not allow for a complete medical assessment. Case will be reassessed if additional information is received. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.